Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan; Forest Laboratories

    • Most Recent Events

    • 07 Aug 2023 Results of pooled post hoc analysis from NCT02670538, NCT02670551 evaluating efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety, published in the International Clinical Psychopharmacology
    • 18 Oct 2022 Results of post hoc analysis of pooled data (NCT01396447, NCT02670538, NCT02670551) assessing which patients with bipolar depression could particularly benefit from 3 mg/d cariprazine presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
    • 05 Oct 2021 Results assessing NCT00488618; NCT01058096; NCT01058668;NCT01396447; NCT02670538 and NCT02670551 assessing efficacy of cariprazine in manic, depressive, and cognitive symptoms in bipolar I disorder in light of its receptor profile, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top